Merkel Cell Carcinoma News and Research

RSS

Promising clinical data of ImmunoGen's lorvotuzumab mertansine to be presented at ESMO conference

ImmunoGen, Inc., a biopharmaceutical company that develops targeted anticancer therapeutics using its Targeted Antibody Payload (TAP) technology, today announced the presentation of encouraging clinical data for the Company's lorvotuzumab mertansine (IMGN901) targeted anticancer compound at the 35th European Society for Medical Oncology (ESMO) Conference being held in Milan, Italy, October 8-12, 2010.

11 Oct 2010

FDA grants orphan drug designation to ImmunoGen's lorvotuzumab mertansine for small-cell lung cancer

ImmunoGen, Inc., a biotechnology company that develops antibody-based targeted anticancer products, today announced that the US Food and Drug Administration (FDA) has granted orphan drug designation to its lorvotuzumab mertansine (formerly IMGN901) product candidate when used for the treatment of small-cell lung cancer (SCLC).

19 Aug 2010

ImmunoGen fourth-quarter 2010 net loss increases to $13.4 million

5 Aug 2010

Immunogen reports a net loss of $12.1 million in third quarter 2010

30 Apr 2010

ImmunoGen receives FDA orphan drug designation for IMGN901 compound in treatment of MCC

ImmunoGen, Inc., a biotechnology company that develops targeted anticancer products using its antibody expertise and Targeted Antibody Payload (TAP) technology, today announced that the US Food and Drug Administration (FDA) has granted orphan drug designation to its IMGN901 compound when used for the treatment of Merkel cell carcinoma (MCC). Through a separate process, the European Union (EU) Committee for Orphan Medicinal Products (COMP) concurrently also granted IMGN901 orphan medicinal product designation for the treatment of MCC.

8 Mar 2010

ImmunoGen reports encouraging clinical data of IMGN901

ImmunoGen, Inc., a biopharmaceutical company that develops targeted anticancer therapeutics, today reported encouraging clinical data with its IMGN901 product candidate in the treatment of relapsed and relapsed/refractory multiple myeloma (MM), including prolonged benefit in patients whose disease had progressed on multiple prior treatment regimens.

6 Dec 2009

ImmunoGen to present IMGN901 clinical data at AACR-NCI-EORTC International Conference

ImmunoGen, Inc., a biopharmaceutical company that develops targeted anticancer therapeutics, announced today that several ImmunoGen poster presentations will be made at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics to be held in Boston, MA, on November 15-19, 2009.

10 Nov 2009

Researchers discover that Merkel cells originate in the skin

Case Western Reserve University School of Medicine assistant professor of pediatrics, neurosciences and otolaryngology, Stephen M. Maricich, M.D., Ph.D., and his team found that Merkel cells originate in the skin, not the neural crest lineage, as previously speculated.

3 Oct 2009

Researchers identify embryonic origin of Merkel cells

Publication in Journal of Cell Biology : researchers from ULB (IRIBHM) identify the embryonic origin of Merkel cells. Their research continue on an extremely aggressive cancer, the Merkel cell carcinoma

30 Sep 2009

The mysterious origin of Merkel cells

A new study resolves a 130-year-old mystery over the developmental origin of specialized skin cells involved in touch sensation. The findings will appear in the October 5, 2009 issue of the Journal of Cell Biology (online September 28).

29 Sep 2009

Virus may play role in causing some cases of squamous cell carcinoma

A virus discovered last year in a rare form of skin cancer has also been found in people with the second most common form of skin cancer among Americans, according to researchers at the Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute.

31 Jul 2009

West Australians above the age of 69 at risk of sun-related skin cancer death

A new Western Australian study has revealed the mortality from non-melanoma skin cancer (NMSC), commonly considered less dangerous than melanoma, is affecting older Australians at a worrying rate.

13 Apr 2008

Previously unknown Merkel cell polyomavirus linked to deadly skin cancer

A new strategy to hunt for human viruses described in this week's issue of the journal Science by the husband-and-wife team who found the cause of Kaposi's sarcoma has revealed a previously unknown virus strongly associated with another rare but deadly skin cancer called Merkel cell carcinoma.

18 Jan 2008